SLC6A4 expression and anti-proliferative responses to serotonin transporter ligands chlomipramine and fluoxetine in primary B-cell malignancies.

Anita Chamba; Michelle Holder; RF Jarrett; L Shield; Kai-Michael Toellner; Mark Drayson; Nicholas Barnes; John Gordon

doi:10.1016/j.leukres.2010.03.007

SLC6A4 expression and anti-proliferative responses to serotonin transporter ligands chlomipramine and fluoxetine in primary B-cell malignancies.

Anita Chamba, Michelle Holder, RF Jarrett, L Shield, Kai-Michael Toellner, Mark Drayson, Nicholas Barnes, John Gordon

Research output: Contribution to journal › Article

12 Citations (Scopus)

Abstract

B-cell lines of diverse neoplastic origin express the serotonin transporter (SERT/SLC6A4) and growth arrest in response to SERT-ligands, including the antidepressants chlomipramine and fluoxetine. Here we detail SLC6A4 transcript (Q-PCR) and protein (FACS) expression in primary cells from patients with: chronic lymphocytic leukaemia; mantle cell lymphoma; follicular lymphoma; Burkitt's lymphoma; and diffuse large B-cell lymphoma. The ability of the SERT-binding antidepressants to impact the growth of these cells when sustained on CD154-transfected fibroblasts was also determined. The results reveal a broad spectrum of primary B-cell malignancies expressing SLC6A4 with a proportion additionally displaying growth arrest on SERT-ligand exposure.

Original language	English
Journal	Leukemia Research
DOIs	https://doi.org/10.1016/j.leukres.2010.03.007
Publication status	Published - 1 Apr 2010

Keywords

Leukaemia
Proliferation
Serotonin transporter
Lymphoma
CD154

Access to Document

10.1016/j.leukres.2010.03.007

Cite this

@article{3e6b48fc65724a399aaf96b9e3e7aeb1,

title = "SLC6A4 expression and anti-proliferative responses to serotonin transporter ligands chlomipramine and fluoxetine in primary B-cell malignancies.",

abstract = "B-cell lines of diverse neoplastic origin express the serotonin transporter (SERT/SLC6A4) and growth arrest in response to SERT-ligands, including the antidepressants chlomipramine and fluoxetine. Here we detail SLC6A4 transcript (Q-PCR) and protein (FACS) expression in primary cells from patients with: chronic lymphocytic leukaemia; mantle cell lymphoma; follicular lymphoma; Burkitt's lymphoma; and diffuse large B-cell lymphoma. The ability of the SERT-binding antidepressants to impact the growth of these cells when sustained on CD154-transfected fibroblasts was also determined. The results reveal a broad spectrum of primary B-cell malignancies expressing SLC6A4 with a proportion additionally displaying growth arrest on SERT-ligand exposure.",

keywords = "Leukaemia, Proliferation, Serotonin transporter, Lymphoma, CD154",

author = "Anita Chamba and Michelle Holder and RF Jarrett and L Shield and Kai-Michael Toellner and Mark Drayson and Nicholas Barnes and John Gordon",

year = "2010",

month = apr,

day = "1",

doi = "10.1016/j.leukres.2010.03.007",

language = "English",

journal = "Leukemia Research",

issn = "1873-5835",

publisher = "Elsevier",

}

TY - JOUR

T1 - SLC6A4 expression and anti-proliferative responses to serotonin transporter ligands chlomipramine and fluoxetine in primary B-cell malignancies.

AU - Chamba, Anita

AU - Holder, Michelle

AU - Jarrett, RF

AU - Shield, L

AU - Toellner, Kai-Michael

AU - Drayson, Mark

AU - Barnes, Nicholas

AU - Gordon, John

PY - 2010/4/1

Y1 - 2010/4/1

N2 - B-cell lines of diverse neoplastic origin express the serotonin transporter (SERT/SLC6A4) and growth arrest in response to SERT-ligands, including the antidepressants chlomipramine and fluoxetine. Here we detail SLC6A4 transcript (Q-PCR) and protein (FACS) expression in primary cells from patients with: chronic lymphocytic leukaemia; mantle cell lymphoma; follicular lymphoma; Burkitt's lymphoma; and diffuse large B-cell lymphoma. The ability of the SERT-binding antidepressants to impact the growth of these cells when sustained on CD154-transfected fibroblasts was also determined. The results reveal a broad spectrum of primary B-cell malignancies expressing SLC6A4 with a proportion additionally displaying growth arrest on SERT-ligand exposure.

AB - B-cell lines of diverse neoplastic origin express the serotonin transporter (SERT/SLC6A4) and growth arrest in response to SERT-ligands, including the antidepressants chlomipramine and fluoxetine. Here we detail SLC6A4 transcript (Q-PCR) and protein (FACS) expression in primary cells from patients with: chronic lymphocytic leukaemia; mantle cell lymphoma; follicular lymphoma; Burkitt's lymphoma; and diffuse large B-cell lymphoma. The ability of the SERT-binding antidepressants to impact the growth of these cells when sustained on CD154-transfected fibroblasts was also determined. The results reveal a broad spectrum of primary B-cell malignancies expressing SLC6A4 with a proportion additionally displaying growth arrest on SERT-ligand exposure.

KW - Leukaemia

KW - Proliferation

KW - Serotonin transporter

KW - Lymphoma

KW - CD154

U2 - 10.1016/j.leukres.2010.03.007

DO - 10.1016/j.leukres.2010.03.007

M3 - Article

C2 - 20363025

SN - 1873-5835

JO - Leukemia Research

JF - Leukemia Research

ER -

SLC6A4 expression and anti-proliferative responses to serotonin transporter ligands chlomipramine and fluoxetine in primary B-cell malignancies.

Abstract

Keywords

Access to Document

Fingerprint

Cite this